Clinical Pipeline

Our partners are advancing several compounds in clinical trials that were the outcome of previous drug discovery collaborations with Astex. The responsibility for developing these products is with our partners.

DiscoveryPhase 1Phase 2Phase 3Marketed

Kisqali® (ribociclib)

CDK4/6 inhibitor (Oncology)
Partner: Novartis


Balversa® (erdafitinib)

FGFr inhibitor (Oncology)
Partner: Janssen


AZD5363 (capivasertib)

PKB/Akt Inhibitor (Oncology)
Partner: AstraZeneca


Multiple Targets and Therapeutic Areas

Partner: GlaxoSmithKline